Harnath Singh, MD
Nephrology · Flagstaff, AZNPI 1538133236
Payments from drug & device makers
Across 71 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$213
- Vifor Pharma, Inc.$211
- Amgen$198
- Otsuka America Pharmaceutical, Inc.$141
- Akebia Therapeutics Inc$106
- OPKO Pharmaceuticals, LLC$92
- plus $498 from 15 others
What the payments were for
- Food & beverage$1,38395%
- Education$785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $213 |
| Vifor Pharma, Inc. | 10 | $211 |
| Amgen(2 entities) | 10 | $198 |
| Otsuka America Pharmaceutical, Inc. | 6 | $141 |
| Akebia Therapeutics Inc | 5 | $106 |
| OPKO Pharmaceuticals, LLC | 5 | $92 |
| Mallinckrodt Hospital Products Inc. | 3 | $81 |
| GSK | 4 | $70 |
| Bayer | 3 | $67 |
| Aurinia Pharma U.S., Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Nxstage Medical, Inc. | 2 | $26 |
| Mallinckrodt Enterprises LLC | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
| Sanofi | 1 | $21 |
| Novartis | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Fresenius USA Marketing, Inc. | 1 | $16 |
How this compares
$1,461 in reported general payments places this provider in the 35th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 37 | $3,528 |
| Calcium Acetate | 21 | $1,509 |
| Allopurinol | 79 | $889 |
| Calcitriol | 32 | $593 |
| Losartan Potassium | 41 | $543 |
| Furosemide | 83 | $515 |
| Lisinopril | 36 | $341 |
| Tamsulosin Hcl | 11 | $244 |
| Amlodipine Besylate | 29 | $167 |
| Carvedilol | 12 | $150 |
| Hydrochlorothiazide | 19 | $115 |
| Metoprolol Tartrate | 20 | $95 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $94 |
| Ciprofloxacin Hcl | 12 | $51 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Flagstaff
- Peter SantosGlendale$3.6M
- Minesh RajpalPeoria$3.6M
- Leslie ThomasPhoenix$3.1M
- Kenneth BorenMesa$1.6M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Mandeep SahaniMesa$945K
- Randy CooperPeoria$837K
- Amit FadiaTucson$396K
- Hassan HachemPhoenix$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.